Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease

NCT06605378

Status	RECRUITING
Sponsor	Ensoma
Enrollment	60 participants

Key Eligibility Criteria

Inclusion (3)

- The participant must have been diagnosed with CGD based on the referring physician's confirmation that NADPH oxidase activity is d5% (i.e., the percentage of dihydrorhodamine-positive \[DHR+\] cells is d5% by flow cytometry) OR based on confirmed pathogenic mutation in a CGD associated gene (CYBB, CYBA, NCF1, NCF2, NCF4, or CYBC1).
- The participant or the participant's legally authorized guardian or representative (if applicable) must be capable of giving signed informed consent.
- The participant (with assistance from the participant's legally authorized guardian/representative or primary caregiver, if applicable) must be capable of complying with the requirements and restrictions listed in the protocol and informed consent form (ICF).

Exclusion (2)

- The participant has undergone an allogeneic bone marrow transplant or investigational gene therapy.
- The participant is unable to comply with the sample collection procedure based on investigator judgment.

Locations (52 total)

Home-based telemedicine, Montgomery, Alabama, United States
Home-based telemedicine, Phoenix, Arizona, United States
Home-based telemedicine, Little Rock, Arkansas, United States
... and 49 more locations